Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome

Autor: Harry C. Dietz, Megan Podowski, Marc K. Halushka, Kathleen L. Gabrielson, Tammy M. Holm, Erin C Klein, Djahida Bedja, David L. Huso, Loretha Myers, Timothy K. Cooper, Luca Carta, Francesco Ramirez, Carla L. Calvi, Ronald D. Cohn, Bart Loeys, Daniel B. Rifkin, Enid Neptune, Daniel P. Judge, Jennifer P Habashi, Guosheng Liu
Rok vydání: 2006
Předmět:
Lung Diseases
musculoskeletal diseases
Marfan syndrome
congenital
hereditary
and neonatal diseases and abnormalities

medicine.medical_specialty
Fibrillin-1
Adrenergic beta-Antagonists
Fibrillins
Loeys–Dietz syndrome
Antibodies
Losartan
Receptor
Angiotensin
Type 1

Article
Marfan Syndrome
Familial thoracic aortic aneurysm
Mice
Aortic aneurysm
Neutralization Tests
Pregnancy
Transforming Growth Factor beta
Internal medicine
medicine
Animals
cardiovascular diseases
skin and connective tissue diseases
Lung
Aorta
Multidisciplinary
Angiotensin II receptor type 1
business.industry
Microfilament Proteins
Elastic Tissue
medicine.disease
Propranolol
Angiotensin II
Aortic Aneurysm
Pregnancy Complications
Pulmonary Alveoli
Disease Models
Animal

Endocrinology
Mutation
cardiovascular system
Female
business
Angiotensin II Type 1 Receptor Blockers
Fibrillin
Signal Transduction
medicine.drug
Zdroj: Science. 312:117-121
ISSN: 1095-9203
0036-8075
Popis: Aortic aneurysm and dissection are manifestations of Marfan syndrome (MFS), a disorder caused by mutations in the gene that encodes fibrillin-1. Selected manifestations of MFS reflect excessive signaling by the transforming growth factor–β (TGF-β) family of cytokines. We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-β signaling and can be prevented by TGF-β antagonists such as TGF-β–neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation. These data suggest that losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with MFS and has the potential to prevent the major life-threatening manifestation of this disorder.
Databáze: OpenAIRE